SG11202108810YA - Use of vibegron to treat overactive bladder - Google Patents

Use of vibegron to treat overactive bladder

Info

Publication number
SG11202108810YA
SG11202108810YA SG11202108810YA SG11202108810YA SG 11202108810Y A SG11202108810Y A SG 11202108810YA SG 11202108810Y A SG11202108810Y A SG 11202108810YA SG 11202108810Y A SG11202108810Y A SG 11202108810YA
Authority
SG
Singapore
Prior art keywords
vibegron
overactive bladder
treat overactive
treat
bladder
Prior art date
Application number
Other languages
English (en)
Inventor
Mudd, Jr
Original Assignee
Urovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences Gmbh filed Critical Urovant Sciences Gmbh
Publication of SG11202108810YA publication Critical patent/SG11202108810YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202108810Y 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder SG11202108810YA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962820230P 2019-03-18 2019-03-18
US201962830302P 2019-04-05 2019-04-05
US201962842435P 2019-05-02 2019-05-02
US201962885767P 2019-08-12 2019-08-12
US201962897019P 2019-09-06 2019-09-06
US201962904429P 2019-09-23 2019-09-23
PCT/IB2020/052484 WO2020188505A1 (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Publications (1)

Publication Number Publication Date
SG11202108810YA true SG11202108810YA (en) 2021-10-28

Family

ID=70166082

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108810Y SG11202108810YA (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Country Status (14)

Country Link
US (1) US20230027066A1 (cg-RX-API-DMAC7.html)
EP (2) EP4763281A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022524576A (cg-RX-API-DMAC7.html)
KR (2) KR20260049872A (cg-RX-API-DMAC7.html)
CN (2) CN121489955A (cg-RX-API-DMAC7.html)
AU (2) AU2020243514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017198A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129024A1 (cg-RX-API-DMAC7.html)
IL (1) IL285910A (cg-RX-API-DMAC7.html)
MX (1) MX2021009488A (cg-RX-API-DMAC7.html)
PH (1) PH12021551975A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108810YA (cg-RX-API-DMAC7.html)
TW (2) TW202506129A (cg-RX-API-DMAC7.html)
WO (1) WO2020188505A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
TW202038963A (zh) 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆(vibegron)於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
TW202245781A (zh) * 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍(vibegron)治療心臟衰竭之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. β−3作動薬および中間体の製造方法
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Kcnq2〜5チャネル関連疾患の予防および/または治療剤
WO2017210696A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US10057209B2 (en) * 2016-07-28 2018-08-21 Qualcomm Incorporated Time-sequenced multi-device address assignment
KR20250099259A (ko) * 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
CN110869053A (zh) * 2017-06-06 2020-03-06 乌洛万特科学有限公司 给药维贝隆以治疗膀胱过度活动症
EP3583905A1 (en) * 2018-06-20 2019-12-25 Arthrex Inc Percutaneous targeting device

Also Published As

Publication number Publication date
TW202102221A (zh) 2021-01-16
AU2025256180A1 (en) 2025-11-13
JP2022524576A (ja) 2022-05-09
US20230027066A1 (en) 2023-01-26
KR20260049872A (ko) 2026-04-14
BR112021017198A2 (pt) 2021-11-16
EP3941473A1 (en) 2022-01-26
EP4763281A2 (en) 2026-06-24
WO2020188505A1 (en) 2020-09-24
IL285910A (en) 2021-10-31
AU2020243514A1 (en) 2021-08-26
CA3129024A1 (en) 2020-09-24
PH12021551975A1 (en) 2022-07-04
CN121489955A (zh) 2026-02-10
CN113840607A (zh) 2021-12-24
MX2021009488A (es) 2021-09-21
KR20210142004A (ko) 2021-11-23
TW202506129A (zh) 2025-02-16
JP2025084777A (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
IL268138A (en) Combinations of cabozantinib and atezolizumab for cancer treatment
IL292810A (en) Therapeutic compounds and methods of use
IL271164A (en) Use of vibegron to treat overactive bladder
GB201804514D0 (en) Treatment of pyroptosis
SG11202103588WA (en) Use of reboxetine to treat narcolepsy
IL278978A (en) Preparations and methods for treating eczema
IL274532A (en) Using the prodrug riluzole to treat ataxias
IL285910A (en) Use of vibegron to treat overactive bladder
IL290983A (en) Treatment methods
IL286697A (en) Neurogulin-4 compounds and methods of use
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
ZA201903795B (en) Treatment of water
GB2589398B (en) Compounds and methods of use
GB201804515D0 (en) Treatment of necroptosis
IL283031A (en) And will grow to treat the symptoms of overactivity in the gland
GB201918879D0 (en) Treatment of chronic pain
IL289338B1 (en) Therapeutic interactions of leucomethylthioninium
ZA202105399B (en) Use of spiropidion
IL281166A (en) Methods for using the phenoxypropylamine compound to treat pain
IL276382A (en) Use of PCBP1 to treat hyperproliferative disease
GB201907305D0 (en) Treatment of conditions
PT4054582T (pt) Combinações terapêuticas de acalabrutinib e capivasertib para tratar malignidades de células b
GB201918853D0 (en) Methods of treatment
SG11202102240YA (en) Methods of treating psoriasis
GB201906975D0 (en) Treatment of ards